Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepafast
- Development stage
- Unknown
- Lead developer
- Bodymed
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Hepafast is a high-protein, high-soluble fiber, and low-carbohydrate meal replacement formula diet designed to support liver fat reduction ('liver fasting' or 'Leberfasten') and weight loss. Developed by Bodymed (acquired by Nestlé Health Science in 2020), Hepafast is typically used as a short-term dietary intervention to reduce hepatic steatosis (fatty liver) and improve metabolic parameters, such as blood glucose, insulin resistance, and blood pressure, in patients with non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes.
- Brand names
- Hepafast
Beyond the preview
Go deeper on Hepafast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hepafast.